dexamethasone
information and resources from the National Cancer Institute
NCI Thesaurus | dexamethasone
A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. NCI Thesaurus | dexamethasone
A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones.
|
|
|
|
news articles
Dexamethasone Induces Connective Tissue Growth Factor Expression ... Feb 28, 2006
Am J Pathology (subscription) In addition, the glucocorticoid dexamethasone (DEX) increased CTGF mRNA levels in the kidneys of C57B6 but not SJL mice and produced intermediate CTGF mRNA ...
Liposomes With Steroid Payloads Target Arthritis Inflammation Mar 29, 2006
CNN In their experiments, the Dutch researchers used RGD peptide liposomes to deliver a dose of dexamethasone phosphate to vascular endothelial cells at the site ...
Fighting inflammation with targeted liposomal therapy Mar 28, 2006
EurekAlert (press release), They chose RGD peptide liposomes to deliver a dose of dexamethasone phosphate (DEXP) to VECs at the site of inflammation in rats with experimental arthritis. ...
FDA Grants Priority Review for REVLIMID(R) sNDA for Treatment of ... Mar 3, 2006
International News Service, The Company is seeking approval to market REVLIMID in combination with dexamethasone as a proposed indication for the treatment of multiple myeloma patients ...
Priority multiple myeloma review for Celgene drug Mar 7, 2006
Pharmaceutical Business Review The company is seeking approval to market Revlimid in combination with dexamethasone in a proposed indication for the treatment of multiple myeloma patients ...
A Novel Aspartic Proteinase-Like Gene Expressed in Stratified ... Mar 24, 2006
Am J Pathology (subscription) ...potential AP-1 target gene because TPA-induced expression in epidermal keratinocytes critically depends on c-Fos, and co-treatment with dexamethasone, a potent ...
High Dose Gleevec® and Low-Dose Chemotherapy Effective for ... Mar 17, 2006
Cancer Consultants (press release), Researchers from France have reported that high-dose Gleevec (imatinib) combined with vincristine and dexamethasone produced complete remissions (CR) in 28 of ...
High-Dose Gleevec® and Low-Dose Chemotherapy Effective for ... Mar 17, 2006
Cancer Consultants (press release), ...trial to evaluate high-doses of Gleevec combined with low doses of the chemotherapy agent vincristine (Oncovin®) and the steroid dexamethasone in patients ...
FDA APPROVES TAXOTERE(R) FOR THE TREATMENT OF PATIENTS WITH ... Mar 24, 2006
PR Newswire (press release), R). Before each TAXOTERE(R) treatment, all patients treated with TAXOTERE(R) must receive another medicine called dexamethasone. ...
Celgene's Revlimid gets priority review Mar 3, 2006
United Press International Celgene's supplemental new drug application (sNDA) seeks approval to use Revlimid in combination with dexamethasone for the treatment of multiple-myeloma ...
Millennium CEO says may form strategic partnership Mar 10, 2006
Reuters Revlimid is used in combination with the chemotherapy dexamethasone, whose side effects in high doses can include paranoia. "If ...
Prevention of Postoperative Nausea and Vomiting with Granisetron ... Mar 21, 2006
Anesthesia & Analgesia (subscription), All subjects received dexamethasone at induction of anesthesia followed by either 12.5 mg of dolasetron or 1 mg of granisetron. ...
Hepatic Arterial Infusion Improves Survival in Metastatic ... Mar 17, 2006
Cancerpage.com, Dr. Kemeny and colleagues compared hepatic arterial infusion treatment with floxuridine, leucovorin, and dexamethasone and with fluorouracil and leucovorin in ...
TAXOTERE(R) Receives US FDA Approval For Use In Advanced Stomach ... Mar 23, 2006
Yahoo! News (press release) Taxotere®. Before each Taxotere® treatment, all patients treated with Taxotere® must receive another medicine called dexamethasone. ...
MultiVu Video Feed: FDA Approves New Treatment For Patients With ... Mar 23, 2006
PR Newswire (press release), ...of the ingredients in Taxotere(R). Before each Taxotere(R) treatment, all patients treated with Taxotere(R) must receive another medicine called dexamethasone. ...
Etoposide-Based Therapy May Reduce Mortality From Bird Flu Mar 1, 2006
Medscape (subscription) ...lymphohistiocytosis (HLH), researchers theorize that severe cases of human H5N1 infection may respond to HLH therapy -- dexamethasone plus etoposide -- along ...
Celgene gets Revlimid priority review Mar 3, 2006
BusinessWeek The new application hopes to use Revlimid along with the steroid dexamethasone to treat multiple myeloma in patients who have received at least one prior ...
Safety of steroids for small babies questioned Mar 6, 2006
Reuters.uk, ...therapy for hypotension. The most commonly used steroid for hypotension was hydrocortisone, followed by dexamethasone. When compared ...
Chemotherapy for Immune Disorder Suggested as Avian Flu Treatment Mar 3, 2006
CNN 90%, the investigators noted. The so-called HLH-94 protocol begins with etoposide and dexamethasone up front. A revised protocol ...
Business briefs Mar 4, 2006
NorthJersey.com, Celgene is seeking clearance to market the drug in combination with dexamethasone, a treatment for certain types of cancer, the Summit-based company said. ...
Controlled Delivery of High vs Low Humidity vs Mist Therapy for ... Mar 14, 2006
Journal of American Medical Association (subscription), ...as were proportions of excellent responders; proportions with croup score of 0 at study conclusion; and proportions receiving dexamethasone, epinephrine, or ...
Doxil® in the VAD Regimen for Myeloma Confirmed Less Toxic Than ... Feb 28, 2006
Cancer Consultants (press release), A US multicenter trial has reported that a regimen of Doxil (pegylated liposomal doxorubicin), vincristine and dexamethasone is associated with less toxicity ...
US Study Fails to Confirm Benefits of Autologous Stem Cell ... Mar 14, 2006
Cancer Consultants (press release), This study called for VAD (vincristine, Adriamycin and dexamethasone) induction and cyclophosphamide/Neupogen® mobilization of peripheral blood stem cells in ...
Keryx Biopharmaceuticals, Inc. Commences Phase 2, Multi-Center ... Mar 2, 2006
PharmaLive.com (press release), DFCI -led phase I/II study evaluating the safety and efficacy of KRX-0401 and bortezomib (Velcade(R)) therapy with or without dexamethasone for patients with ...
Thalidomide Not Associated with Survival Improvement in Multiple ... Mar 13, 2006
Cancer Consultants (press release), Traditionally patients receive induction therapy with VAD (vincristine, Adriamycin and dexamethasone) followed by single or tandem transplants with high-dose ...
Celgene’s New Cancer Drug Gets Priority Handling Mar 3, 2006
Business New Jersey (subscription), Celgene is looking to market the drug in combination with dexamethasone, a steroid that breaks down fat, to help patients with multiple myeloma who have ...
Revlimid® Plus Dexamethasone Shows Promise in Treatment of ... 21 Dec 2005
Cancer Consultants (press release), Researchers recently reported promising results from a phase III clinical trial of Revlimid® (lenalidomide) plus dexamethasone for the treatment of multiple ...
ADVANCES IN TREATING ASTHMA 21 Dec 2005
British Satellite News, When the Vitamin D3 was added, along with the drug dexamethasone, the results in this study offered new hope for patients who have failed to respond to current ...
Combination Dexamethasone and Lenaidomide For Multiple Myeloma " ... Dec 12, 2005
DG News ATLANTA, GA -- December 12, 2005 -- Treatment of multiple myeloma with a combination of dexamethasone and the investigational drug lenalidomide (Revlimid(R ...
REVLIMID(R) IMPROVES OVERALL SURVIVAL AND DELAYS TIME TO DISEASE ... Dec 11, 2005
ITNews, Nasdaq: CELG) announced updated clinical data from two Phase III pivotal studies evaluating REVLIMID (lenalidomide) plus dexamethasone in previously treated ...
Bortezomib (Velcade) Shows Strong Survival Benefit in Relapsed ... Dec 13, 2005
DG News 333) 1.3 mg/m 2 IV on days 1, 4, 8, 11 every 3 weeks for 8 cycles, followed by 3 cycles on days 1, 8, 15, 22 every 5 weeks, or to receive dexamethasone 40 mg ...
GlycoGenesys, Inc. GCS-100 Cancer Drug Candidate Subject of ... Dec 15, 2005
Genetic Engineering News, ...and Modulation of Carbohydrate-Binding Protein Galectin-3 in Multiple Myeloma Cells by Combined Treatment with GCS-100 and Dexamethasone", was authored by ...
Advanced multiple myeloma: Revlimid improves overall survival and ... Dec 12, 2005
Xagena.it, Updated clinical data from two Phase III pivotal studies evaluating Revlimid ( Lenalidomide ) plus Dexamethasone in previously treated multiple myeloma ...
REVLIMID(R) Clinical Results as Oral Treatment Regimen in Newly ... Dec 13, 2005
PR Newswire (press release), ...that new data evaluating clinical results on the treatment of newly diagnosed multiple myeloma patients with REVLIMID (lenalidomide) and dexamethasone as an ...
Consistently High Complete and Overall Response Rates in Newly ... Dec 13, 2005
PR Newswire (press release), VELCADE Alone and In Combination with Dexamethasone (abstract #783) In an update of a phase II trial conducted by Sundar Jagannath, MD, of St. ...
Millennium: Velcade set for cancer consolidation Dec 13, 2005
Pharmaceutical Business Review ...demonstrated a median overall survival of 30 months in patients treated with Velcade (bortezomib), compared with 24 months for those treated with dexamethasone ...
Researchers Discover Improved Treatment Option for Patients with ... Dec 11, 2005
PR Newswire (press release), Traditional therapy for patients whose multiple myeloma has either relapsed or is resistant to treatment is the high-dose steroid dexamethasone. ...
Valley becoming hotbed of clinical research Dec 19, 2005
Phoenix Business Journal, Mitroxantrone for acute leukemia, Carboplatin for ovarian cancer, Revlemid for myelodysplastic anemia, Abraxene for breast cancer, and Dexamethasone, which is ...
New Data Show Median 30-Month Survival With VELCADE(R) (Bortezomib ... Dec 11, 2005
PR Newswire (press release), ...- Single-agent data demonstrate six-month survival advantage over dexamethasone - ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. ...
Consistently High Complete and Overall Response Rates in Newly ... Dec 13, 2005
Biotech Intelligence (press release), Vincent's Comprehensive Cancer Center in New York, data on VELCADE alone and in combination with dexamethasone in patients with previously untreated ...
Altered vascular contractility in adult female rats with ... Dec 19, 2005
Journal of Endocrinology ...in adulthood. Pregnant dams received dexamethasone (Dex; 100mg/ kg, sc) or vehicle (control) daily throughout pregnancy. Blood pressure ...
Senesco Technologies Announces Results of Bone Marrow Cancer Cell ... Dec 19, 2005
dBusinessNews Newark (press release), ...interest in that it has proven to be very difficult to induce apoptosis in myeloma cells in the presence of IL-6 with standard therapies such as dexamethasone ...
New Data on VELCADE(R) (bortezomib) for Injection to Be Presented ... Dec 6, 2005
PR Newswire (press release), ...include: Multiple Myeloma * Updated survival and safety data from the APEX trial -- Single-agent survival rates versus high-dose dexamethasone (abstract #2547 ...
Vitamin boost for asthma therapy Dec 7, 2005
Scotsman, ...to steroid treatments, T-cells taken from patients who are steroid-resistant did not produce IL-10 when cultured in a petri dish with the steroid dexamethasone ...
Survival boosted by six months with Velcade Dec 14, 2005
Cancerfacts.com, ...provides longer survival, greater one-year survival rates, better response rates and longer time to progression than treatment with high-dose dexamethasone. ...
BOULDER, Colorado, December 13 /PRNewswire/ -- Dec 13, 2005
ITNews, A total of 125 evaluable patients, randomized to receive either thalidomide-dexamethasone (TD) or melphalan-prednisone (MP), demonstrated a overall response ...
Celtic Pharma Completes Acquisition of Exclusive Worldwide Rights ... Nov 28, 2005
Yahoo! News (press release) The two studies include the "acute protocol" (XERECEPT or dexamethasone needed immediately) and a "chronic protocol" or a dex-sparing trial (patients already ...
Source: sanofi-aventis Dec 8, 2005
Yahoo! News (press release) TAXOTERE®. Before each TAXOTERE® treatment, all patients treated with TAXOTERE® must receive another medicine called dexamethasone. ...
GlaxoSmithKline Presents Rapidly Expanding Pipeline of Oncology ... Nov 30, 2005
Finanzen.net, ...approximately 1,200 patients combined), presented at today's seminar, showed that the use of casopitant in combination with Zofran and dexamethasone produced a ...
Scientists air more reasons to take vitamin D Dec 12, 2005
Knoxville News Sentinel (subscription), After taking the supplement, all patients were found to have immune cells that were more responsive to the steroid dexamethasone. ...
New Data Show Median 30-Month Survival With VELCADE(R) (Bortezomib ... Dec 11, 2005
Yahoo! News (press release) The updated results, based on median follow-up of 22 months, from the APEX study continue to show VELCADE is superior to high-dose dexamethasone in overall ...
Interim Analysis of Phase III Study Shows TAXOTERE(R)-Based ... Dec 8, 2005
PR Newswire (press release), R). Before each TAXOTERE(R) treatment, all patients treated with TAXOTERE(R) must receive another medicine called dexamethasone. ...
Glaxo Bullish on Cancer Drugs Nov 30, 2005
Red Herring, On Casopitant, clinical data showed that when combined with the nausea reducing drug Zofran and synthetic steroid dexamethasone, patients experienced ...
Bird flu: a new dread - III Dec 2, 2005
GreaterKashmir.com (press release), ...phase of ARDS survived. In a randomized trial in Vietnam, all four patients given dexamethasone died. Interferon alfa possesses ...
Glucocorticoids enhance cytotoxicity of cisplatin via suppression ... Nov 28, 2005
Journal of Endocrinology Our previous study demonstrated that dexamethasone (DEX) enhances the cytotoxicity to cisplatin in a GR-rich human cervical carcinoma cell line, SiHa. ...
Long-term remission after autologous peripheral blood stem cell ... Nov 24, 2005
Nature.com (subscription), ...courses of dose-modified CHASE therapy (cytarabine 130 mg/m 2 3 days, cyclophosphamide 800 mg/m 2 1 day, etoposide 70 mg/m 2 3 days and dexamethasone 25 mg 3 ...
|
|
